Related Experiment Videos
Basic science and research in renal cell carcinoma: from workbench to bedside
Axel Heidenreich1, Andres J Schrader, Zoltan Varga
1Department of Urology and Pediatric Urology, Philipps-University, Baldingerstrasse, 35043 Marburg, Germany. heidenre@post.med.uni-marburg.de
Current Opinion in Urology
|October 16, 2003
Summary
Improving outcomes for renal cell carcinoma (RCC) requires early diagnosis and accurate progression prediction. Recent research offers novel molecular diagnostics and targeted therapies for this common male cancer.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Renal cell carcinoma (RCC) is the third most common cancer in men.
- Radical surgery is the only curative treatment, with poor prognosis for metastatic disease (5-year survival <20%).
- Improved outcomes necessitate advancements in early diagnosis, progression prediction, and molecularly targeted therapies.
Purpose of the Study:
- To review recent developments in diagnostic and therapeutic options for renal cell carcinoma.
- To highlight molecular insights into RCC pathogenesis and progression.
- To identify clinically useful tools for early detection and treatment selection.
Main Methods:
- Detection of circulating tumor cells (CTCs) and DNA.
- Analysis of genetic alterations and mutations in tumor DNA and urine.
- Evaluation of immune response markers and HLA haplotypes.
- Assessment of targeted therapies including monoclonal antibodies and small molecule inhibitors.
Main Results:
- Circulating biomarkers (MN/CAIX gene, tumor DNA, urine proteins) show potential for early RCC diagnosis.
- Signal transducer and activator of transcription (STAT) correlates with relapse.
- HLA class II haplotypes (DQA1, DQB1) predict response to cytokine therapy.
- Monoclonal antibodies targeting EGFR and VEGFR, antisense oligodeoxynucleotides, and proteasome inhibitors show promising therapeutic effects.
Conclusions:
- Recent research has identified clinically useful diagnostic and therapeutic strategies for RCC.
- These advancements reflect a deeper understanding of the molecular basis of RCC pathogenesis and progression.
- Novel molecular approaches offer improved options for early diagnosis, prognosis, and treatment of renal cell carcinoma.